Trial Profile
Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia; Thalassaemia
- Focus Pharmacodynamics
- Acronyms CVR
- 03 May 2023 Status changed from recruiting to completed.
- 13 Jul 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 07 May 2021 Planned End Date changed from 1 Mar 2023 to 1 Dec 2022.